Wall Street analysts forecast that Syros Pharmaceuticals Inc (NASDAQ:SYRS) will announce earnings of ($0.50) per share for the current quarter, Zacks reports. Four analysts have made estimates for Syros Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.53) and the highest estimate coming in at ($0.44). Syros Pharmaceuticals posted earnings of ($0.58) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 13.8%. The company is scheduled to announce its next quarterly earnings results on Monday, March 11th.
According to Zacks, analysts expect that Syros Pharmaceuticals will report full year earnings of ($1.86) per share for the current year, with EPS estimates ranging from ($1.92) to ($1.77). For the next financial year, analysts forecast that the company will report earnings of ($1.93) per share, with EPS estimates ranging from ($2.12) to ($1.67). Zacks’ EPS averages are an average based on a survey of research analysts that that provide coverage for Syros Pharmaceuticals.
Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings results on Thursday, November 1st. The company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.02). The business had revenue of $0.41 million for the quarter, compared to the consensus estimate of $0.72 million.
Several equities research analysts have commented on SYRS shares. BidaskClub raised shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, August 31st. Zacks Investment Research lowered shares of Syros Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, October 10th. Cann reaffirmed a “buy” rating and issued a $26.00 price target on shares of Syros Pharmaceuticals in a report on Tuesday, August 7th. Cowen reaffirmed a “buy” rating on shares of Syros Pharmaceuticals in a report on Tuesday, July 17th. Finally, Roth Capital raised shares of Syros Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $12.00 price target on the stock in a report on Monday. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $19.00.
Large investors have recently bought and sold shares of the business. Wedge Capital Management L L P NC purchased a new stake in shares of Syros Pharmaceuticals during the 3rd quarter worth about $731,000. Alps Advisors Inc. boosted its stake in shares of Syros Pharmaceuticals by 26.0% during the 3rd quarter. Alps Advisors Inc. now owns 59,553 shares of the company’s stock worth $709,000 after acquiring an additional 12,280 shares in the last quarter. Northern Trust Corp boosted its stake in shares of Syros Pharmaceuticals by 52.2% during the 2nd quarter. Northern Trust Corp now owns 275,638 shares of the company’s stock worth $2,814,000 after acquiring an additional 94,548 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Syros Pharmaceuticals by 36.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 70,592 shares of the company’s stock worth $720,000 after acquiring an additional 19,005 shares in the last quarter. Finally, Millennium Management LLC boosted its stake in shares of Syros Pharmaceuticals by 129.3% during the 2nd quarter. Millennium Management LLC now owns 375,466 shares of the company’s stock worth $3,834,000 after acquiring an additional 211,696 shares in the last quarter. 60.74% of the stock is currently owned by institutional investors.
NASDAQ:SYRS opened at $8.06 on Wednesday. Syros Pharmaceuticals has a one year low of $6.25 and a one year high of $15.88. The firm has a market capitalization of $261.16 million, a price-to-earnings ratio of -3.78 and a beta of 0.78.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML.
Further Reading: Dollar Cost Averaging
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.